

Isabelle Ray-Coquard

President of the GINECO group, Professor of medical oncology in University Claude Bernard Lyon I and medical oncologist in the Comprehensive Cancer Center: Centre Leon Bérard (CLB) Lyon France

Born: 07-10 -1967 Nationality: French Married, 6 children (3 + 3)

Summary

Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the independent factors that determine medical practices in oncology. She also received Master's degrees in statistics in 1995 and in medical economy in 1996. From 2008 to 2013, she has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national network dedicated to diagnosis and management of the rare gynecological cancer (www.ovaire-rare.org), a network funded by the INCA commission. At the Groupe d'investigateurs national evaluation des cancers de l'ovaire (GINECO), she has been active in the translational research advisory committee, the scientific committee, and as a chairman of endometrial cancer subgroup and the rare tumors committee. Since 2002, she is also developing translational research dedicated to ovarian cancer with the INSERM within the CRCL directed by A Puisieux within the CLB campus, and more directly with the research on rare gyn cancer biology (Carcinosarcoma, Granulosa cell tumors..). From 2009 to 2018, she was the chairman of the rare cancer working group from GCIG (gynaecological cancer intergroup) dedicated to clinical trials in the field of all rare gynaecological cancers. She is the current President of the GINECO group. She is an active member of a number of professional groups, including the American Society of Clinical Oncology, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation and the European Society of Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO).

University and hospital Positions

- 2005 - : Head of the EMS Research group EA2574 Univ. Cl. Bernard Lyon I (Centre Léon Bérard, CLB)
- 2008 - 2013 Head of the French NCI (INCa) Gynaecologic Research group
- 2010 – 2020 Faculty Member of the European Society of Medical Oncology (ESMO) Faculty for Gynecological Cancer
- 2010 - Director of the Network of Reference Centers for rare Gyn cancer (TMRO/TMRG) (22 centers, www.ovaire-rare.org)
- 2014 - Professor of Medicine in medical oncology; University Claude Bernard Lyon I.
- 2019 – President of the GINECO group

Fundamental Research activities

- 1996-1999: Ph.D: determining factors for medical practice in oncology
- 2005 - : Chair of the EMS Unit (medical practices and organization in oncology), EA 7425
- 2015-: Co chair of the EAM (University supported research unit) HESPER

Clinical Research activities

- 1999 - : investigator of the EORTC group for the STBSG group
- 2000 - : investigator of the GINECO group
- Since 2000, between 100 and 200 patients included in clinical trial per year
- Since 2005, Principal investigator of phase I, II, III (national & international trials)
- 2012- 2018: Chairman of the Rare Tumor Committee of Gynecological Cancer InterGroup (GCIG)
- 2017, Chair of the rare ovarian group for the gynecological rare tumor group within EURACAN (SANTE-ERN@ec.europa.eu)

Pure Academic trial research (on going trials and Sponsor & PI (international trials))

- 2013 - Alienor trial (randomized phase II for sex cords stromal tumor, international cooperation)
- 2014 - HGUS trial (EORTC 62613) dedicated to undifferentiated uterine sarcoma (randomized phase II, international collaboration) recruitment 34 pts on going
- 2015- 2019: PAOLA1 trial (randomized phase III in 1st line EOC evaluating combination of olaparib). ESMO 2019 Presidential session & N Engl J Med 2019
- 2016- NeoPembrOv trial (randomized phase II trial) in 1st line EOC management.
- 2019- ROCSAn trial phase III dedicated to Carcinosarcoma including grant from EU dedicated to translational research
- 2020- COLIBRI trial, a phase II trial dedicated to early stage cervical cancer
- 2020- GYNET trial RHU proof of concept NP137+Pembrolizumab+CT in advanced and recurrent cervix and endometrial carcinoma. Randomized phase II trial.

Scientific Societies and Academic expert group

Member of the following scientific societies:

- 1997 - American Society of Clinical Oncology (ASCO)
- 2000 - European Society for Medical Oncology (ESMO)
- 2000 - Société Française du Cancer (SFC)
- 2000 - Connective Tissue Oncology Society (CTOS)
- 2010 - European Society of Gynecology Obstetric (ESGO)

Publications Index

- Web of Science H factor 70
- Google Scholar H factor 78

Clinical Activities

- Management of gynecological cancers and sarcoma patients (outpatient activity, consultation, 2nd advices)
- Centre Leon Berard Coordinator of the Multidisciplinary Board dedicated to gynecological cancers and rare cancers (weekly meeting)
- Coordinator of the National Multidisciplinary Board dedicated to gynecological rare cancers (weekly meeting)
- Active member of several multidisciplinary tumor board in the Rhone Alpes region (monthly)
- Participation to the multidisciplinary tumor board dedicated to sarcoma patients, molecular tumor board, Euracan multidisciplinary tumor board dedicated to rare Gyn cancers (monthly)
- Domain leader of the GYN rare tumor for EURACAN network

Educational activities

- University Claude Bernard, Lyon & regional activity
 - Medical oncology education for Medical students
 - Coordination of a graduate Unit dedicated to medical students to develop learning in clinical research for oncology during the 3rd year to the 6th year in Medical school process
 - Medical conferences dedicated to Oncology (every 3 months)
 - Direct supervision of the Young medical oncologists (8 young medical oncologist (MO) per year)
 - Regional seminar (annually) with young MO and fellows dedicated to medical oncology education
- National level
 - French national learning (presence or @learning) for Medical Oncology for young specialists
 - Direct supervision of the Young medical oncologists from other part of France (2 young MO per year)
 - Inter University Graduate diploma for Gyn cancer management (Paris, Lyon, Nantes)
 - National course for all French young MO every year (topic: Gyn cancer, rare tumors, sarcoma)
- International Level
 - Direct supervision of the Young medical oncologists from Europe or other part of the world (1 or 2 young MO per year at maximum)
 - Gynecology Cancer Academy (GCA) Mentor supported by ENOT network. GCA dedicated to young investigators at the EU level for clinical research in gynecology cancer. (bi annual since 2012)
 - ESMO preceptorship dedicated to Ovarian cancer (every 3 years)
 - ESO/ESMO/RCE annual meeting dedicated to rare cancer (annual)
 - ESGO faculty for rare cancers with a SoA meeting organizer in 2018 Lyon France
 - Speaker training for Ovarian cancer (annually since 2015) (supported by Industry)
 - Faculty of ICACT congress (2005 to 2015) for gynecological cancers
 - Continuous educational sessions at ASCO (regular invitation), ESMO, ESGO as faculty member since several years)

Mentoring

- PhD
 - As mentor (since 2010) : 10 students
 - As assessor 7 students
- Medical Oncology Graduate
 - As Mentor 15 students since 2005
 - As assessor 10 students
- Medical students
 - 10 students per year in the Oncology research of my institution. Goal to develop knowledge, expertise and Oral presentation expertise in the field of oncology research (clinical and fundamental)

Guidelines & Conference of Consensus

Coordination of the French Guidelines for all rare Gyn cancer (since 2010) and for Epithelial carcinoma since 2010
ESMO guidelines for rare ovarian cancers (2018) ; ESGO/ESMO for ovarian carcinoma (2019)
Coordination of GCIG guidelines dedicated to rare gynecological cancers (since 2014-).
Participation to the GCIG guidelines dedicated to ovarian carcinoma (every 5 years)

Books and Chapters

Advances for management of Ovarian cancers, Springer 2016
Ovarian Cancers supported by ESMO, chapter 2017
Collaborations with D Gershenson (MD Anderson) Rare ovarian cancer, chapter 2014

Public and Patients advocacy groups

Annual meetings in France and EU for Ovarian cancers and sarcoma (DAM's, Info Sarcome, IMAGYN, Engage, Spaen ...)

Selection of Publications 2014 to 2020 (as 1st or last author or supporting mentoring of young MO)

- A1. Pujade-lauraine e, Hilpert f, Weber b, Reuss a, Poveda a, Kristensen g, Sorio r, Vergote i, Witteveen p, bamias a, Pereira d, Wimberger p, Oaknin a, Mirza mr, Follana p, Bollag d, **Ray-Coquard I.** Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. *J Clin Oncol.* 2014 Mar 17.
- A2. **Heudel PE**, Cousin P, Lurkin A, Crochet C, Ducimetiere F, Collard O, De Laroche G, Biron P, Meeus P, Thiesse P, Bergeron C, Vaz G, Mithieux F, Farsi F, Fayet Y, Gilly FN, Cellier D, Blay JY, **Ray-Coquard I.** Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region. *Int J Clin Oncol.* 2014 Aug;19(4):744-52.
- A3. **Philip CA**, Pautier P, Duffaud F, **Ray-Coquard I.** High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches. *Curr Oncol Rep.* 2014 Oct;16(10):405.
- A4. **Eberst L**, Crochet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Bérard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, **Ray-Coquard I.** The off-label use of targeted therapies in sarcomas: the OUTC'S program. *BMC Cancer.* 2014 Nov 24;14:870.
- A5. **Perrier L**, Buja A, Mastrangelo G, Baron P, Ducimetière F, Pauwels PJ, Rossi C, Gilly F, Martin A, Favier B, Farsi F, Laramas M, Baldo V, Collard O, Cellier D, Blay JY, **Ray-Coquard I.** Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. *BMC Health Serv Res.* 2014 Nov 18;14(1):537.
- A6. Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, **Ray-Coquard I.** Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus. *Int J Gynecol Cancer.* 2014 Nov;24(9 Suppl 3):S73-7.
- A7. Hensley ML, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, **Ray-Coquard I.** Gynecologic CancerInterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. *Int J Gynecol Cancer.* 2014 Nov;24(9 Suppl 3):S61-6.
- A8. **Ray-Coquard I**, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanica D, Colombo N. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. *Int J Gynecol Cancer.* 2014 Nov;24(9 Suppl 3):S42-7.
- A9. **Ray-Coquard I**, Ledermann J. International Journal of Gynecological Cancer. Editorial. *Int J Gynecol Cancer.* 2014 Nov;24(9 Suppl 3):S2-4.
- A10. **Emin L**, Meeus P, Beurrier F, Ferraioli D, Carrabin N, **Ray-Coquard I**, Treilleux I, Chopin N. [Postoperative morbidities after modified posterior pelvicexenteration for ovarian cancer]. *Gynecol Obstet Fertil.* 2015 May;43(5):342-7.
- A11. **Gouvent T**, **Ray-Coquard I**, Borel S, Haddad V, Devouassoux-Shisheboran M, Vacher-Lavenu MC, Pujade-Lauraine E, Savina A, Maillet D, Gillet G, Treilleux I, Rimokh R. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study. *Histopathology.* 2016 Jan;68(2):279-85.
- A12. **Ray-Coquard IL**, Domont J, Tresch-Brunel E, Bompas E, Cassier PA, Mir O, Piperno-Neumann S, Italiano A, Chevreau C, Cupissol D, Bertucci F, Bay JO, Collard O, Saada-Bouzid E, Isambert N, Delambre C, Clisant S, Le Cesne A, Blay JY, Penel N. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. *J Clin Oncol.* 2015 Sep 1;33(25):2797-802
- A13. Penel-Page M, **Ray-Coquard I**, Larcade J, **Girodet M**, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thys A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). *BMC Cancer.* 2015 Nov 5;15:854.
- A14. **Ray-Coquard I**, **Rizzo E**, Blay JY, Casali P, Judson I, Hansen AK, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Litière S, Rutkowski P, ohenberger P, Gronchi A, van der Graaf WT. Impact of chemotherapy in uterine sarcoma (Uts):review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma(STS) patients treated with first line chemotherapy. *Gynecol Oncol.* 2016 Jul;142(1):95-101.
- A15. **Benson C**, **Ray-Coquard I**, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, Gil T, Piperno-Neumann S, Marréaud S, Dewji MR, van der Graaf WT. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. *Gynecol Oncol.* 2016 Jul;142(1):89-94.

- A16. Ballinger ML, Goode DL, **Ray-Coquard I**, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. *Lancet Oncol.* 2016 Sep;17(9):1261-71.
- A17. **Leary AF**, Quinn M, Fujiwara K, Coleman RL, Kohn E, Sugiyama T, Glasspool R, **Ray-Coquard I**, Colombo N, Bacon M, Zeimet A, Westermann A, Gomez-Garcia E, Provencher D, Welch S, Small W, Millan D, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.. 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours. *Ann Oncol.* 2016 Dec 19.
- A18. Blay JY, **Brahmi M**, **Ray-Coquard I**. European Journal of Cancer's Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. *Eur J Cancer.* 2017 Jan;70:83-86. doi: 10.1016/j.ejca.2016.07.028.
- A19. **Heudel PE**, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, **Ray-Coquard I**. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. *Br J Cancer.* 2017 Jan;116(3):303-309.
- A20. **Derbel O**, Heudel PE, Crochet C, Meeus P, Vaz G, Biron P, Cassier P, Decouvelaere AV, Ranchere-Vince D, Collard O, De Laroche E, Thiesse P, Farsi F, Cellier D, Gilly FN, Blay JY, **Ray-Coquard I**. Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). *PLoS One.* 2017 Feb 3;12(2):e0158406.
- A21. **Ray-Coquard I**, **Collard O**, Ducimetiere F, Laramas M, Mercier F, Ladarré N, Manson S, Tehard B, Clippe S, Suchaud JP, Stefani L, Blay JY. Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). *BMC Cancer.* 2017 Feb 7;17(1):111.
- A22. **Trédan O**, Ménétrier-Caux C, **Ray-Coquard I**, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. *Ann Oncol.* 2017 Mar 24.
- A23. **Savina M**, Le Cesne A, Blay JY, **Ray-Coquard I**, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honoré C, Sargos P, Sunyach MP, Le Péchoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAsarc observational study. *BMC Med.* 2017 Apr 10;15(1):78.
- A24. **Bétrian S**, Bergeron C, Blay JY, Bompas E, Cassier PA, Chevallier L, Fayette J, Girodet M, Guillemet C, Le Cesne A, Marec-Berard P, **Ray-Coquard I**, Chevreau C. Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's). *Clin Sarcoma Res.* 2017 May 10;7:10.
- A25. **Ray-Coquard I**, Pujade Lauraine E, Le Cesne A, Pautier P, Vacher Lavenue MC, Trama A, Casali P, Coindre JM, Blay JY. Improving treatment results with reference centres for rare cancers: where do we stand? *Eur J Cancer.* 2017 May;77:90-98.
- A26. **Chiannilkulchai N**, Pautier P, Genestie C, Bats AS, Vacher-Lavenu MC, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefevre-Plesse C, Henno S, Leblanc E, Lemaire AS, Averous G, Kurtz JE, **Ray-Coquard I**. Networking for ovarian rare tumors: a significant breakthrough improving disease management. *Ann Oncol.* 2017 Jun 1;28(6):1274-1279.
- A27. **Labidi-Galy SI**, Olivier T, Rodrigues M, Ferraioli D, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger SJ, Meeus P, Merald P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, **Ray-Coquard I**. Location of mutation in BRCA2 gene and survival in patients with ovarian cancer. *Clin Cancer Res.* 2017 Oct 30.
- A28. **Ray-Coquard I**, Trama A, Seckl MJ, Fotopoulos C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol.* 2017 Nov 3. pii: S0748-7983(17)30947-2.
- A29. George S, Serrano C, Hensley ML, **Ray-Coquard I**. Soft Tissue and Uterine Leiomyosarcoma. *J Clin Oncol.* 2017 Dec 8;JCO2017759845.
- A30. **Rousset-Jablonski C**, Reynaud Q, Nove-Josserand R, **Ray-Coquard I**, Mekki Y, Gofquier F, Durieu I; Study conducted in Lyon France. High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. *Eur J Obstet Gynecol Reprod Biol.* 2017 Dec 9;221:40-45.
- A31. **Romeo C**, Joly F, **Ray-Coquard I**, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocaru O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARGAGY-GINECO phase IB-II trial. *Gynecol Oncol.* 2018 Nov 14.
- A32. **Girodet M**, Bouhnik AD, Mancini J, Peretti-Watel P, Bendiane MK, **Ray-Coquard I**, Preau M. Sexual desire of French representative prostate cancer survivors 2 years after diagnosis (the VICAN survey). *Support Care Cancer.* 2018 Nov 8.
- A33. **Fayet Y**, Coindre JM, Dalban C, Gouin F, De Pinieux G, Farsi F, Ducimetière F, Chemin-Airiau C, Jean-Denis M, Chabaud S, Blay JY, **Ray-Coquard I**. Geographical Accessibility of the Referral Networks in France. Intermediate Results from the IGÉAS Research Program. *Int J Environ Res Public Health.* 2018 Oct 10;15(10). pii: E2204.
- A34. **Gantzer J**, **Ray-Coquard I**. Gynecological sarcomas: what's new in 2018, a brief review of published literature. *Curr Opin Oncol.* 2018 Jul;30(4):246-251.
- A35. **Ray-Coquard I**, **Serre D**, Reichardt P, Martín-Broto J, Bauer S. Options for treating different soft tissue sarcoma subtypes. *Future Oncol.* 2018 May;14(10S):25-49.
- A36. Rasmussen V, Forrest LE, Rogasik M, **Girodet M**, Meeus P, Sunyach MP, Blay JY, Bally O, Brahmi M, Ballinger ML, Niedermayr E, Thomas DM, Halliday J, James P, **Ray-Coquard I**, Young MA; International Sarcoma Kindred Study. A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. *Per Med.* 2018 Jan;15(1):13-24.
- A37. **Perrier L**, Rasclé P, Morelle M, Toulmonde M, Ranchere Vince D, Le Cesne A, Terrier P, Neuville A, Meeus P, Farsi F, Ducimetière F, Blay JY, **Ray Coquard I**, Coindre JM. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. *PLoS One.* 2018 Apr 5;13(4):e0193330.
- A38. **Loretz M**, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, **Ray-Coquard I**, Joly Lobbedez F. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]. *Bull Cancer.* 2018 May;105(5):465-474

- A39. Huguet M, Perrier L, Bally O, Benayoun D, De Saint Hilaire P, Beal Ardisson D, Morelle M, Havet N, Joutard X, Meeus P, Gabelle P, Provençal J, Chauleur C, Glehen O, Charreton A, Farsi F, **Ray-Coquard** I. Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhône-Alpes region of France. *BMC Health Serv Res.* 2018 Jan 4;18(1):3
- A40. Rousset-Jablonski C, Reynaud Q, Nove-Josserand R, **Ray-Coquard** I, Mekki Y, Golfier F, Durieu I; Study conducted in Lyon France. High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. *Eur J Obstet Gynecol Reprod Biol.* 2018 Feb;221:40-45
- A41. Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, **Ray-Coquard** I. Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. *Clin Cancer Res.* 2018 Jan 15;24(2):326-333.
- A42. Rousset-Jablonski C, Reynaud Q, Perceval M, Nove-Josserand R, Durupt S, **v Ray-Coquard** I, Golfier F, Durieu I. Improvement in contraceptive coverage and gynecological care of adult women with cystic fibrosis following the implementation of an on-site gynecological consultation. *Contraception.* 2019 Nov 28. pii: S0010-7824(19)30448-2.
- A43. Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. *Gynecol Oncol.* 2019 Nov 18. pii: S0090-8258(19)31670-1.
- A44. Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. *Gynecol Oncol.* 2019 Nov;155(2):262-269.
- A45. Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. *Front Oncol.* 2019 Sep 10;9:832.
- A46. Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, Rogasik M, Salles G, Anglaret B, Freycon C, Corm S, Faurie P, Cornillon J, Michallet AS, Chassagne-Clément C, Berger F, Ray-Coquard IL. Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region. *J Adolesc Young Adult Oncol.* 2019 Aug 14.
- A47. Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, Paindavoine S, Pérol D, Baudet C, Attignon V, Pissaloux D, Heudel P, You B, Leyronnas C, Collard O, Trédan O, Bonnin N, Long J, Jacquin JP, Cassier PA, Derbel O, Freyer G, Viari A, Blay JY, Ray-Coquard I. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. *Eur J Cancer.* 2019 Sep;118:156-165.
- A48. Vanacker H, Romeo C, Ray-Coquard I. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when? *Curr Opin Oncol.* 2019 Sep;31(5):394-403.
- A49. Swaliduz A, Souquet PJ, Pérol M, Moro-Sibilot D, Schiffler C, Chabaud S, Fayet Y, Rogasik M, Labrosse H, Farsi F, Brun P, Decroisette C, Bombaron P, Bringuier PP, Haddad V, Forest F, Peoc'h M, Lantuejoul S, de Fraipont F, Ray-Coquard I, Fournel P. Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. *Future Oncol.* 2019 Jun;15(18):2139-2149.
- A50. Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Daraï E, Chabbert-Buffet N, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, Thibault MR, Ferron G, Devouassoux M, Kurtz JE, Provansal M, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. *Eur J Cancer.* 2019 Jul;116:35-44.
- A51. Laurent M, Brahmi M, Dufresne A, Meeus P, Karanian M, Ray-Coquard I, Blay JY. Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTS)-review and perspectives. *Transl Gastroenterol Hepatol.* 2019 Apr 9;4:24.
- A52. Meurer M, Floquet A, Ray-Coquard I, Bertucci F, Auriche M, Cordoba A, Piperno-Neumann S, Salas S, Delannes M, Chevalier T, Italiano A, Blay JY, Mancini J, Pautier P, Duffaud F. Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. *Int J Gynecol Cancer.* 2019 May;29(4):691-698.
- A53. Franceschi T, Durieux E, Morel AP, de Saint Hilaire P, Ray-Coquard I, Puisieux A, Devouassoux-Shisheboran M. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas. *Virchows Arch.* 2019 Jul;475(1):85-94.
- A54. de la Motte Rouge T, Ray-Coquard I, You B. [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. *Gynecol Obstet Fertil Senol.* 2019 Feb;47(2):222-237.
- A55. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *Oncologist.* 2019 Jul;24(7):e536-e541. doi:
- A56. Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berthon-Rigaud D, Kalbacher E, Cojocaru O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial. *Gynecol Oncol.* 2019 Jan;152(1):68-75.
- A57. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. *Cancer Discov.* 2019 Feb;9(2):210-219.
- A58. Girodet M, Bouhnik AD, Mancini J, Peretti-Watel P, Bendiane MK, Ray-Coquard I, Preau M. Sexual desire of French representative prostate cancer survivors 2 years after diagnosis (the VICAN survey). *Support Care Cancer.* 2019 Jul;27(7):2517-2524.
- A59. Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. *Int J Gynecol Cancer.* 2019 Nov;29(9):1396-1404.

- A60. Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, Penel N, Ryckewaert T, Honoré C, Bertucci F, Monneur A, Salas S, Duffaud F, Saada-Bouzid E, Isambert N, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. *Ann Surg Oncol.* 2019 Nov 26.
- A61. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefevre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med.* 2019 Dec 19;381(25):2416-2428.
- A62. Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, Penel N, Bompas E, Rios M, Le Cesne A, Italiano A, Anract P, de Pinieux G, Collard O, Bertucci F, Duffaud F, Le Deley MC, Delaye J, Brugieres L, Blay JY. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. *Int J Cancer.* 2020 Jan 15;146(2):413-423.
- A63. Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottевanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomized placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. *Int J Cancer.* 2020 Jan 15;146(2):439-448.
- A64. Marec-Berard P, Laurence V, Occean BV, Ray-Coquard I, Linassier C, Corradini N, Collard O, Chaigneau L, Cupissol D, Kerbrat P, Saada-Bouzid E, Delcambre C, Gouin F, Guillemet C, Jimenez M, Lervat C, Gaspar N, Le Deley MC, Brugieres L, Piperno-Neumann S. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin- Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. *J Adolesc Young Adult Oncol.* 2020 Apr;9(2):172-182.
- A65. Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. *Gynecol Oncol.* 2020 Feb;156(2):377-386.
- A66. Roussel-Jablonski C, Reynaud Q, Perceval M, Nove-Josserand R, Durupt S, Ray- Coquard I, Goflier F, Durieu I. Improvement in contraceptive coverage and gynecological care of adult women with cystic fibrosis following the implementation of an on-site gynecological consultation. *Contraception.* 2020 Mar;101(3):183-188. doi: 10.1016/j.contraception.2019.10.014.
- A67. Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Bozec L, Eymard JC, Saada E, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancerFrench Sarcoma Group study (LMS03 study). *Eur J Cancer.* 2020 Jan;125:31-37.
- A68. Michel P, Fraticelli L, Parneix P, Daucourt V, Farges O, Gasquet I, Occelli P, Ray-Coquard I, Duclos A; QUID Workgroup. Assessing the performance of indicators during their life cycle: the mixed QUID method. *Int J Qual Health Care.* 2020 Apr 21;32(1):12-19. doi: 10.1093/intqhc/mzz090. PMID: 31841143.
- A69. Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupiigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. *Eur J Cancer.* 2020 Feb;126:45-55.
- A70. Patrikidou A, Chaigneau L, Isambert N, Kitikidou K, Shanley R, Ray-Coquard I, Valentin T, Malivoir B, Laigre M, Bay JO, Moureau-Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Guillemet C, Duffaud F, Hügli A, Le Pechoux C, Dhermain F, Blay JY, Sperduto PW, Le Cesne A. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). *BMC Cancer.* 2020 Feb 12;20(1):117.
- A71. Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, Michot A, Penel N, Honoré C, Owen C, Bertucci F, Salas S, Saada-Bouzid E, Valentin T, Bompas E, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. *Ann Surg Oncol.* 2020 Jun;27(6):1818-1827.
- A72. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumberg M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the science. *Gynecol Oncol.* 2020 Mar;156(3):715-725.
- A73. Italiano A, Mir O, Mathoulin-Pélissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacqueument H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2020 Mar;21(3):446-455.
- A74. D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litrière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer.* 2020 Jun 1;126(11):2637-2647.
- A75. Lenck C, Chopin N, Gouy S, Bonsang-Kitzis H, Martinez-Gomez C, Radosevic-Robin N, Martin S, Lefevre-Plesse C, Lambaudie E, Leblanc E, Guyon F, Classe JM, Ramanah R, Beurrier F, Angeles MA, Pomel C, Joly F, de la Motte Rouge T, Provansal M, Lesoin A, Floquet A, Berton D, Kalbacher E, Chakiba C, Meeus P, Selle F, Treilleux I, Lecuru F, Pautier P, Ray-Coquard I. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study. *Gynecol Oncol.* 2020 Apr;157(1):78-84.
- A76. Amadeo B, Penel N, Coindre JM, Ray-Coquard I, Ligier K, Delafosse P, Bouvier AM, Plouvier S, Gallet J, Lacourt A, Coureau G, Monnereau A, Mathoulin-Pélissier S, Desandes E. Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). *BMC Cancer.* 2020 Mar 6;20(1):190.
- A77. Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, Lang JD, Orlando KA, Oza AM, Pautier P, Ray-Coquard I, Trent JM, Witcher M, Witkowski L, McCluggage WG, Levine DA, Foulkes WD, Weissman BE. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. *Clin Cancer Res.* 2020 Aug 1;26(15):3908-3917.
- A78. Gershenson DM, Okamoto A, Ray-Coquard I. Rare Gynecologic Tumors: Coming of Age. *Gynecol Oncol.* 2020 Apr;157(1):1-2

- A79. Chevrot A, Pouget N, Bats AS, Huchon C, Guyon F, Chopin N, Rousset-Jablonski C, Beurrier F, Lambaudie E, Provansal M, Sabatier R, Heinemann M, Ngo C, Bonsang-Kitzis H, Lecuru F, Bailly E, Ferron G, Cornou C, Lardin E, Leblanc E, Philip CA, Ray-Coquard I, Hequet D. Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. *Gynecol Oncol*. 2020 Apr;157(1):29-35.
- A80. Ray-Coquard I, Péröl D, Pujade-Lauraine E. PARP Inhibitors in Ovarian Cancer. *Reply*. *N Engl J Med*. 2020 Apr 16;382(16):1574-1575.
- A81. Marec-Bérard P, Aho S, Berger C, Plantaz D, Aho-Glelé LS, Ducimetière F, Duclos A, Fontanière B, Collard O, Blay JY, Sunyach MP, Chotel F, Bergeron C, Dijoud F, Vaz G, Ray-Coquard I. Clinical management of adolescents and young adults suffering from sarcoma in the French Rhône-Alpes region: A prospective exhaustive cohort with 10 years follow up. *Eur J Surg Oncol*. 2020 Jul;46(7):1301-1309.
- A82. Concin N, Ray-Coquard I, Glasspool RM, Braicu E, Farrelly L, Votan B, Mirza MR, Gonzalez Martin A, Vergote I, Pignata S. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development. *Int J Gynecol Cancer*. 2020 Jun;30(6):730-734.
- A83. Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. *Curr Opin Oncol*. 2020 Jun 5. doi: 10.1097/CCO.0000000000000644
- A84. Debuquoys C, Romeo C, Vanacker H, Ray-Coquard I. Rare ovarian tumors: an update on diagnosis and treatment. *Int J Gynecol Cancer*. 2020 Jun;30(6):879-887.
- A85. Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. *Curr Opin Oncol*. 2020 Jul;32(4):321-331.
- A86. Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penit AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachet T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. *Eur J Cancer*. 2020 Aug;135:251-259.
- A87. Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. *Cancer Treat Rev*. 2020 Jul;87:102040.
- A88. Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommooss S, Leung SCY, Senz J, Lum A, Chow V, Suderuddin H, Mackenzie R, George J; AOCS Group, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva De Silva D, Ramón Y Cajal T, García-Donas J, Hernando Polo S, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubinski J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, García MJ, Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecný GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic gene expression signature for high-grade serous ovarian cancer. *Ann Oncol*. 2020 Sep;31(9):1240-1250.
- A89. Ray-Coquard I, Hatcher H, Bompas E, Casado A, Westermann A, Isambert N, Casali PG, Pratap S, Stark D, Valverde C, Anand A, Huizing M, Floquet A, Lindner L, Hermes B, Seddon B, Coens C, Jones R, Reed N. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). *Int J Gynecol Cancer*. 2020 Oct;30(10):1633-1637.
- A90. Brahmi M, Cassier P, Dufresne A, Chabaud S, Karanian M, Meurgey A, Bouhamama A, Gouin F, Vaz G, Garret J, Sunyach MP, Dupré A, Marec-Bérard P, Corradini N, Perol D, Ray-Coquard I, Blay JY. Long term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGC). *PLoS One*. 2020 May 20;15(5):e0233046.
- A91. Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommooss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, Senz J, Lum A, Chow V, Suderuddin H, Mackenzie R, Leong SCY, Liu G, Johnson D, Chen B, Group A, Alsop J, Banerjee SN, Behrens S, Bodelon C, Brand AH, Brinton L, Carney ME, Chiew YE, Cushing-Haugen KL, Cybulski C, Ennis D, Fereday S, Fortner RT, García-Donas J, Gentry-Maharaj A, Glasspool R, Goranova T, Greene CS, Haluska P, Harris HR, Hendley J, Hernandez BY, Herpel E, Jimenez-Linan M, Karpinskyj C, Kaufmann SH, Keeney GL, Kennedy CJ, Köbel M, Koziak JM, Larson MC, Lester J, Lewsley LA, Lissowska J, Lubinski J, Luk H, Macintyre G, Mahner S, McNeish IA, Menkiszak J, Nevins N, Osorio A, Oszurek O, Palacios J, Hinsley S, Pearce CL, Pike MC, Piskorz AM, Ray-Coquard I, Rhenius V, Rodriguez-Antona C, Sharma R, Sherman ME, De Silva D, Singh N, Sinn P, Slamon D, Song H, Steed H, Stronach EA, Thompson PJ, Trabert B, Traficante N, Tseng CC, Widschwendter M, Wilkens LR, Winham SJ, Winterhoff B, Beeghly-Fadiel A, Benitez J, Berchuck A, Brenton JD, Brown R, Chang-Claude J, Chenevix-Trench G, DeFazio A, Fasching PA, García MJ, Gayther SA, Goodman MT, Gronwald J, Henderson MJ, Karlan BY, Kelemen LE, Menon U, Orsulic S, Pharoah PDP, Wentzensen N, Wu AH, Schildkraut JM, Rossing MA, Konecný GE, Huntsman DG, Huang RY, Goode EL, Ramus SJ, Doherty JA, Bowtell DD, Anglesio MS. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clin Cancer Res*. 2020 Oct 15;26(20):5411-5423.
- A92. Robelin P, Tod M, Colombe O, Lachuer J, Ray-Coquard I, Rauglaudre G, Joly F, Chevalier-Place A, Combe P, Lortholary A, Hamizi S, Raban N, Ferron G, Meunier J, Berton-Rigaud D, Alexandre J, Kaminsky MC, Dubot C, Leary A, Malaurie E, You B. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). *Gynecol Oncol*. 2020 Oct;159(1):256-263.
- A93. Blanc-Durand F, Lefevre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux É, Berton D, Bello-Roufai D, Guillemet C, Dupre PF, Faller É, Alexandre J, Hardy-Bressard AC, Collard O, Fabbro M, Provansal M, Kalbacher E, Genestie C, Pautier P. Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT). *Gynecol Oncol*. 2020 Oct;159(1):129-135.
- A94. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. *J Clin Oncol*. 2020 Nov 10;38(32):3753-3762.
- A95. You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurtre M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colombe O. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. *Clin Cancer Res*. 2020 Sep 1;26(17):4625-4632.

- A96. Ferraioli D, Bally O, Meeus P, Benayoun D, Bakrin N, De Saint Hilaire P, Beal Ardisson D, Provençal J, Barletta H, Mousseau M, Chauleur C, Verbaere S, Knibiehly A, Fuso L, Charreton A, Devouassoux-Shisheboran M, Chopin N, Glehen O, Labrosse-Canat H, Farsi F, Ray-Coquard I. Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region. *Eur J Cancer Care (Engl)*. 2020
- A97. Heudel P, Chabaud S, Perol D, Ray-Coquard I, Blay JY. Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer. *Ann Oncol*. 2020 Dec;31(12):1773-1775.
- A98. Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. *Semin Cancer Biol*. 2020 Sep 12:S1044-579X(20)30193-0.
- A99. Brahmi M, Franceschi T, Treilleux I, Pissaloux D, Ray-Coquard I, Dufresne A, Vanacker H, Carboneaux M, Meeus P, Sunyach MP, Bouhamama A, Karanian M, Meurgey A, Blay JY, Tirode F. Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History. *Cancers (Basel)*. 2020 Sep 11;12(9):2604.
- A100. Yazigi A, Lecointe-Artzner E, Cesne AL, Ray-Coquard I, Blay JY. Pregnancy in Women with Metastatic Sarcomas. *Oncologist*. 2020 Dec;25(12):e2010-e2012. doi: 10.1002/onco.13529. Epub 2020 Sep 28. PMID: 32949182.
- A101. Assaad S, Fuhrmann C, Avrillon V, Ray-Coquard I, Blay JY. Risk of death of patients with cancer presenting with severe symptoms of infection, with or without documented COVID-19: In reply to van Dam et al. *Eur J Cancer*. 2020 Nov;139:68-69.
- A102. Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. *Ann Oncol*. 2020 Dec;31(12):1606-1622.
- A103. Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, Gladieff L, Lück HJ, Floquet A, Chevalier-Place A, Schnelzer A, Pignata S, Selle F, Sehouli J, Brocard F, Mangili G, Pautier P, De Giorgi U, Provansal M, Heudel PE. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate among Patients with Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. *JAMA Oncol*. 2020 Oct 8;6(12):1-9.
- A104. Ray-Coquard I, Vanacker H, Le Saux O, Tredan O. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready? *EBioMedicine*. 2020 Nov; 61:103046. doi: 10.1016/j.ebiom.2020.103046.
- A105. Lorusso D, Ray-Coquard I, and Oaknin A, Banerjee S. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? *ESMO Open*. 2020 Oct;5(5):e000924. doi: 10.1136/esmoopen-2020-000924.
- A106. Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieveure D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19 collaborators/investigators. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). *Eur J Cancer*. 2020 Dec;141:62-81
- A107. Lamort-Bouché M, Chardon M, Kellou N, Ray-Coquard I, Colin C, Letrilliart L. Cancer screening and follow-up in general practice: A French nationwide cross-sectional study. *Eur J Gen Pract*. 2020 Dec;26(1):95-101.
- A108. Morfouace M, Stevovic A, Vinches M, Golfinopoulos V, Jin DX, Holmes O, Erlich R, Fayette J, Croce S, Ray-Coquard I, Girard N, Blay JY. First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. *ESMO Open*. 2020 Dec;5(6):e001075.
- A109. Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I. First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion. *ESMO Open*. 2020 Nov;5(6):e001110.
- A110. den Hollander D, Fiore M, Martin-Broto J, Kasper B, Casado Herraez A, Kulis D, Nixon I, Sodergren SC, Eichler M, van Houdt WJ, Desar IME, Ray-Coquard I, Piccinin C, Kosela-Paterczyk H, Miah A, Hentschel L, Singer S, Wilson R, van der Graaf WTA, Husson O. Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. *Cancers (Basel)*. 2020 Dec 22;13(1):1.
- A111. Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. *J Natl Cancer Inst*. 2020 Dec 29:djaa193.
- A112. Crombé A, Kind M, Ray-Coquard I, Isambert N, Chevreau C, André T, Lebbe C, Cesne AL, Bompas E, Piperno-Neumann S, Saada E, Bouhamama A, Blay JY, Italiano A; French Sarcoma Group. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. *AJR Am J Roentgenol*. 2020 Dec;215(6):1539-1548.

International Oral presentations

- Invited speaker approximatively 10 to 20 per year
- Poster, Oral, education ASCO/ESMO between 3 to 10 per year

Research Collaborations

- National
 - INSERM, CNRS, Cancer registries, Comprehensive cancer centers network (Unicancer), Curie Institut, French cooperative groups (GINECO, GSF), National cancer Institute (Inca)
- International
 - ENGOT, EORTC, Veneto University, Milan University, Geneva University, Barcelona University, Milan Cancer Institute, Italian, German and Belgium Government, Rare Care network, Euracan, ESGO, GCIG, NCI, MD Anderson, IRCI, ANZGOG, JSMO, Shanghai University, Singapore University,

Malaysia, Mexican Group, Dubai, China Shanghai University, MITO, Mango, NSGO, NOGGO, AGO, ISGO, CEECOG, Ludemann Consortium, JGOG, Tawain group.

Research Contracts

- Public (French or European community) 1000 K€ per year for translational research & rare cancer
- Private (Pharma's or Private Institutions) between 1000 to 6000K€ per year for clinical trials

Scientific Committee (member or President) & Expertise's

- France : Centre Oscar LAMBERT, GINECO, Sentinelles, ARC
- Ad Boards & consulting : Novartis, Lilly, Astra Zeneca, Clovis, Roche, Pharma mar, Netris Pharma, Amgen, Pfizer, GSK, Genmab, AbbVie, BMS, Bayer, Merrimack, Sanofi, Vifor, Boehringer, Merck Serono, MSD, Mersana, Deciphera, Oxnea.
- IDMC AthenD, ATHENA trial, Gannet trial, Advaxis
- Reviewing/Editorial: JCO, Lancet Oncol, Nature Med, Ann Oncol, Eur J Cancer, Cancer, BMJ, BMC, IJGC